In an exploratory phase (phase I) study[27] in which the serum level of CEACAM1 was evaluated to determine whether it could be used to discriminate lung cancer patients from health donors, we set our sample size as recommended by Obuchowski et al.[28]. The gene discussed is CEACAM1; the disease is lung cancer.